Telix Calls Shareholder Meeting on Proposed US$1.65 Billion ITM Acquisition
TLX: $13.13 -2.60% · MC: $4.7B
Telix Pharmaceuticals will hold a general meeting in Melbourne and online on 1 December to seek approval for matters related to its proposed acquisition of ITM Isotope Technologies Munich. The September agreement provides for US$1.65 billion upfront and up to US$700 million in contingent payments tied to regulatory and sales milestones for ITM-11. Telix says shareholders holding over 93% of ITM have agreed to the transaction, and management estimates the combined business would generate more than US$1.3 billion in revenue and other income in 2026.

Comments